Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

SOHO 2020 | Targeting p53 in MDS

David Sallman • 2 Sep 2020
SOHO 2020
Myelodysplastic Syndromes Azacitidine Decitabine

David Sallman, MD, H. Lee Moffitt Cancer Center, Tampa, FL, discusses p53 mutations in the context of patients with myelodysplastic syndromes (MDS) and it’s association with survival. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from David Sallman

2:08
Hematological response to frontline treatment in LR-MDS is associated with better OS
David Sallman • 9 Dec 2023
1:58
Canakinumab plus darbepoetin in patients with LR-MDS following ESA failure
David Sallman • 9 Dec 2023
2:49
Front-line treatment options for HR-MDS: can we move past azacitidine?
David Sallman • 9 Dec 2023
Transplantation & immunotherapies
Charles Craddock et al. • 4 Sep 2023

Related Videos

2:22
Haplo-SCT for older patients with AML/MDS, and should age be a barrier to transplantation?
Raynier Devillier • 15 Apr 2024
2:31
Emerging treatment options for patients with ESA-refractory MDS: luspatercept & imetelstat
Eva Hellström-Lindberg • 11 Apr 2024
1:49
The unmet needs of patients with VEXAS syndrome
Maël Heiblig • 17 Apr 2024
1:25
The role of the bone marrow microenvironment in hematological malignancies
Manja Wobus • 17 Apr 2024
The content of VJHemOnc is intended for healthcare professionals